Federal Register / Vol. 89, No. 43 / Monday, March 4, 2024 / Notices 15597 

manufacturing costs and simplify 

logistics, especially in regions where 

malaria is endemic. Additionally, the 

adaptability of these immunogens for 

integration with nanoparticle platforms 

could further amplify their 

immunogenicity, paving the way for 

more robust and lasting protection 

against malaria. This innovation can 

potentially transform malaria 

prevention and control, offering a more 

effective, stable, and cost-efficient 

solution to a disease that continues to 

impact millions worldwide. 

This technology is available for 

licensing for commercial development 

in accordance with 35 U.S.C. 209 and 37 

CFR part 404, as well as for further 

development and evaluation under a 

research collaboration. 

Potential Commercial Applications 

• Stable single-component AMA1– 

RON2 immunogens hold promise for 

improving malaria prevention and 

control efforts in endemic regions 

around the world. 

Competitive Advantages 

• No blood-stage malaria vaccine has 

been approved. This technology offers a 

competitive edge over other vaccine 

candidates in development through its 

easily manufactured single-component 

AMA1–RON2 design that elicits a 

potent broadly neutralizing response 

that is better than competing candidates. 

Development Stage 

• The efficacy of stable singlecomponent AMA1–RON2 immunogens 

has been validated in rat and rabbit 

models. Following identification of the 

most cost-effective platform for vaccine 

production, the immunogens will be 

advanced for virulent parasite challenge 

studies in Aotus monkeys and towards 

human trials. 

Inventors: Niraj Tolia, Ph.D., Thayne 

Dickey, Ph.D., Palak Patel, Ph.D., all of 

NIAID. 

Publications: Patel, P. N. et. al., 

Structure-based design of a strain 

transcending AMA1–RON2L malaria 

vaccine. Nat. Commun. 14, 5345 (2023). 

Intellectual Property: HHS Reference 

No. E–096–2023–0–US–01US–01; US 

Provisional Application No. 63/524,522, 

filed on June 30, 2023. 

Licensing Contact: To license this 

technology, please contact Peter Tung at 

240–669–5483 or peter.tung@nih.gov, 

and reference E–096–2023. 

Collaborative Research Opportunity: 

The National Institute of Allergy and 

Infectious Diseases is seeking statements 

of capability or interest from parties 

interested in collaborative research to 

further develop, evaluate, or 

commercialize this technology. For 

collaboration opportunities, please 

contact Peter Tung at 240–669–5483 or 

peter.tung@nih.gov. 

Dated: February 27, 2024. 

Surekha Vathyam, 

Deputy Director, Technology Transfer and 

Intellectual Property Office, National Institute 

of Allergy and Infectious Diseases. 

[FR Doc. 2024–04441 Filed 3–1–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Topics in Hepatology, 

Pharmacology, and Toxicology. 

Date: March 25–26, 2024. 

Time: 9:30 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Jodie Michelle Fleming, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 812R, 

Bethesda, MD 20892, (301) 867–5309, 

flemingjm@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; PAR–20– 

117: Maximizing Investigators’ Research 

Award for Early-Stage Investigators. 

Date: March 25–26, 2024. 

Time: 10:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Jonathan Arias, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5170, 

MSC 7840, Bethesda, MD 20892, (301) 435– 

2406, ariasj@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Topics in Disease Control and 

Applied Immunology. 

Date: March 25, 2024. 

Time: 10:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: David Balasundaram, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5189, 

MSC 7840, Bethesda, MD 20892, 301–435– 

1022, balasundaramd@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Molecular Genetics and Evolution. 

Date: March 27, 2024. 

Time: 8:30 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Karobi Moitra, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, 6701 Rockledge Drive, 

Bethesda, MD 20892, (301) 480–6893, karobi.

moitra@nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; NIH 

Research Enhancement Award (R15) in 

Oncological Sciences. 

Date: March 27, 2024. 

Time: 9:00 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Byung Min Chung, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20892, (301) 496–4056, justin.chung@

nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Cell and 

Developmental AREA/REAP Review. 

Date: March 27, 2024. 

Time: 10:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Robert O’Hagan, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20892, (240) 909–6378, ohaganr2@

csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Developmental Biology. 

Date: March 27, 2024. 

Time: 11:00 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Virtual Meeting). 


khammond on DSKJM1Z7X2PROD with NOTICES
15598 Federal Register / Vol. 89, No. 43 / Monday, March 4, 2024 / Notices 

Contact Person: Jimok Kim, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6107 Rockledge Drive, Bethesda, MD 

20892, (301) 402–8559, jimok.kim@nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; PAR 20– 

298: Development of the Fetal Immune 

System. 

Date: March 27, 2024. 

Time: 1:00 p.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Elaine Sierra-Rivera, Ph.D., 

IRG Chief, Center for Scientific Review, 

National Institutes of Health, 6701 Rockledge 

Drive, Room 6182, Bethesda, MD 20892, 

(301) 435–2514, riverase@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Topics in Pathogenic Eukaryotes. 

Date: March 27, 2024. 

Time: 1:30 p.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Liying Guo, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4198, 

MSC 7812, Bethesda, MD 20892, (301) 827– 

7728, lguo@mail.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Neurodevelopment, 

Neurodegeneration, and Glia Biology. 

Date: March 27, 2024. 

Time: 12:00 p.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Jacek Topczewski, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 1002A1, 

Bethesda, MD 20892, (301) 594–7574, 

topczewskij2@csr.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: February 27, 2024. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–04445 Filed 3–1–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Mental Health; 

Notice of Closed Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Mental Health Special Emphasis Panel; 

Developing Measures to Advance Access and 

Quality in Global Mental Health Services. 

Date: April 2, 2024. 

Time: 1:00 p.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852. 

Contact Person: Regina Dolan-Sewell, 

Ph.D., Scientific Review Officer, Division of 

Extramural Activities, National Institute of 

Mental Health, National Institutes of Health, 

Neuroscience Center, 6001 Executive Blvd., 

Bethesda, MD 20852, (240) 796–6785, regina.

dolan-sewell@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program No. 93.242, Mental Health Research 

Grants, National Institutes of Health, HHS) 

Dated: February 27, 2024. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–04443 Filed 3–1–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Establishment of the of the Board of 

Scientific Counselors, National 

Institute on Minority Health and Health 

Disparities and National Institute of 

Nursing Research 

Pursuant to the Federal Advisory 

Committee Act, as amended (5 U.S.C. 

1001–1014), the Director of the National 

Institutes of Health (NIH) announces the 

establishment of the Board of Scientific 

Counselors, National Institute on 

Minority Health and Health Disparities 

and National Institute of Nursing 

Research, as authorized by 42 U.S.C. 

282(b)(16), section 402(b)(16) of the 

Public Health Service Act, as amended. 

The Director, NIH, has determined 

that the Board of Scientific Counselors, 

National Institute on Minority Health 

and Health Disparities and National 

Institute of Nursing Research is in the 

public interest in connection with the 

performance of duties imposed on NIH 

by law and that these duties can best be 

performed through the advice and 

counsel of the committee. 

The committee will review and 

evaluate the intramural programs and 

the work of tenured, tenure track, and 

staff scientists and physicians and shall 

also, as requested by the Director, NIH, 

undertake peer review of extramural 

funding applications as required by 

section 492 of the Public Health Service 

Act, as amended. 

Inquiries may be directed to Claire 

Harris, Director, Office of Federal 

Advisory Committee Policy, Office of 

the Director, National Institutes of 

Health, 6701 Democracy Boulevard, 

Suite 1000, Bethesda, Maryland 20892 

(Mail code 4875), Telephone (301) 496– 

2123, or Claire.Harris@nih.gov. 

Dated: February 27, 2024. 

Monica M. Bertagnolli, 

Director, National Institutes of Health. 

[FR Doc. 2024–04496 Filed 3–1–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Diabetes and 

Digestive and Kidney Diseases; Notice 

of Closed Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel; RFA–DK22–021 

Collaborative Research Using Biosamples 


khammond on DSKJM1Z7X2PROD with NOTICES